Vkorc1 and cyp2c9 polymorphisms are associated with warfarin dose requirements in turkish patients

You have forgotten your username or password, we can .My Menu Saved Items дё­ж–‡(з®ЂдЅ") дё­ж–‡(з№Ѓй«") English Deutsch н•њкµ­м–ґ ж—Ґжњ¬иЄћ Franais Espaol Ш§Щ„Ш№Ш±ШЁЩЉШ© Р СѓСЃСЃРєРёР№ Journal Article _VKORC1_ AND _CYP2C9_ POLYMORPHISMS ARE ASSOCIATED WITH WARFARIN DOSE REQUIREMENTS IN TURKISH PATIENTS Journal Publisher Springer Berlin / Heidelberg ISSN 0031-6970 (Print) 1432-1041 (Online) Category Pharmacogenetics DOI 10.Subject Collection SpringerLink Date Tuesday, June 10, 2008 PHARMACOGENETICS _VKORC1_ and _CYP2C9_ polymorphisms are associated with warfarin dose requirements in Turkish patients G.T.Langaee2, H.N.T.A.Hatemi1, A.S.And J.Johnson2, 3 (1) University of Istanbul, Istanbul, Turkey (2) Department of Pharmacy Practice and Center for Pharmacogenomics, University of Florida College of Pharmacy, Gainesville, FL, USA (3) Department of Pharmacy Practice, University of Florida College of Pharmacy, P.Box 100486, Gainesville, FL 32610, USA RECEIVED: 18 January 2008 ACCEPTED: 12 May 2008 PUBLISHED ONLINE: 10 June 2008 Abstract Objectives The objective of this study was to determine the quantitative influence of vitamin K epoxide reductaseplex subunit 1 (_VKORC1_) and cytochrome P450 2C9 (_CYP_ _2C9_) polymorphisms on warfarin dose requirements in Turkish patients.Methods A total of 205 patients taking warfarin for >2 months were enrolled in the study.Acid (DNA) samples from these patients were genotyped for polymorphisms in _VKORC1_ and _CYP2C9_ genes.Linear regression analysis was used to determine the independent effects of genetic and non-genetic factors on mean warfarin dose requirements.Results The _VKORC1_ promoter polymorphism (3673 G>A) was associated with differences in weekly mean varfarin dose: for GG genotype the dose was 43.For GA genotype 33.And for AA genoype 25.(_P_ Within all content Within this journal Export this article Export this article as RIS Text В© Springer.
Read more Solodyn (minocycline hcl) extended release tablets 90 mg
Get more Halozyme therapeutics announces phase i clinical trial results demonstrating that the combination of recombinant human hyaluronidase (rhuph20) with humulin r and with humalog yields faster, more physiologic insulin kinetics and better predictability